semaglutide and tirzepatide. Maintenance therapy on or tirzepatide Tirzepatide Outperforms Semaglutide in Blood

Stat Med

Work and social schedules significantly impact timing decisions

It sets clear expectations and keeps motivation high

These pharmacokinetic properties enable therapeutic drug levels with weekly administration, improving patient adherence compared to daily injectable peptides

You can read the abstract of this article at In the SURPASS-4 trial, the dual GIP and GLP-1 receptor agonist tirzepatide demonstrated superior reductions in HbA1c concentrations, bodyweight, and blood pressure compared to titrated daily insulin glargine in individuals with type 2 diabetes and cardiovascular risk

These studies tested tirzepatide specifically in people with obesity and moderate-to-severe obstructive sleep apnea